These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 6525465)

  • 1. The value of a radioimmunological monitoring in cancer patients treated with interferon alpha.
    Bernier J; Reuter A; Vrindts-Gevaert Y; Franchimont P; Pouillart P; Bretaudeau B; Falcoff E; Magdelenat H
    Bull Cancer; 1984; 71(5):405-11. PubMed ID: 6525465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunoassay of leukocyte (alpha) interferon and its application to some clinical conditions.
    Bernier J; Reuter A; Vrindts-Gevaert Y; Franchimont P
    J Nucl Med; 1984 Jul; 25(7):765-72. PubMed ID: 6737075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Phase-1 study of the tolerance for increasing doses of recombinant human alpha 2 interferon in patients with advanced cancer].
    Bretaudeau B; Palangie T; Giralt E; Jouve M; Pouillart P; Falcoff E; Fridman WH; Magdelenat H; Derstepani L; Laurent T
    Bull Cancer; 1984; 71(1):40-9. PubMed ID: 6713113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials.
    Ernstoff MS; Fusi S; Kirkwood JM
    J Biol Response Mod; 1983; 2(6):540-7. PubMed ID: 6607324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A sensitive radioimmunoassay for alpha-interferon: circulating alpha-interferon-like substance in the plasma of healthy individuals and rheumatoid arthritis patients.
    Shiozawa S; Chihara K; Shiozawa K; Fujita T; Ikegami H; Koyama S; Kurimoto M
    Clin Exp Immunol; 1986 Oct; 66(1):77-87. PubMed ID: 3802576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
    Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
    J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrapleural application of natural IFN alpha in breast cancer patients with pleural carcinomatosis. Monitoring of immunotherapy by assaying serum interferon levels.
    Mazuran R; Ikić-Sutlić M; Jereb B; Stabuc B; Krasovec MU; Cerar O; Soos E
    J Biol Regul Homeost Agents; 1992; 6(2):46-52. PubMed ID: 1414464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon.
    Lotzová E; Savary CA; Quesada JR; Gutterman JU; Hersh EM
    J Natl Cancer Inst; 1983 Nov; 71(5):903-10. PubMed ID: 6580490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-alpha in serum and carcinomatous pleural effusion after repeated intrapleural injections of antitumor agents.
    Kaneto E; Sasaki H; Tamura I; Kurimura O; Kurimura T
    Biken J; 1983 Jun; 26(2):99-102. PubMed ID: 6318725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological effects of recombinant interferon-alpha 2 in cancer patients.
    Hengst JC; Kempf RA; Kan-Mitchell J; Pham AT; Grunberg SM; Kortes VL; Mitchell MS
    J Biol Response Mod; 1983; 2(6):516-27. PubMed ID: 6663321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of natural killing activity by lymphoblastoid interferon in cancer patients.
    Koren HS; Brandt CP; Tso CY; Laszlo J
    J Biol Response Mod; 1983; 2(2):151-65. PubMed ID: 6644332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of human leukocyte interferon in patients with advanced cancer.
    Horning SJ; Levine JF; Meyer M; Merigan TC; Rosenberg SA
    J Biol Response Mod; 1983; 2(1):47-56. PubMed ID: 6196450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy.
    Balan V; Nelson DR; Sulkowski MS; Everson GT; Lambiase LR; Wiesner RH; Dickson RC; Post AB; Redfield RR; Davis GL; Neumann AU; Osborn BL; Freimuth WW; Subramanian GM
    Antivir Ther; 2006; 11(1):35-45. PubMed ID: 16518958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of human natural killer cell cytotoxicity by recombinant leukocyte interferon clone A.
    Lotzová E; Savary CA; Gutterman JU; Quesada JR; Hersh EM
    J Biol Response Mod; 1983; 2(5):482-96. PubMed ID: 6644351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.
    Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T
    Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic study of partially pure gamma-interferon in cancer patients.
    Gutterman JU; Rosenblum MG; Rios A; Fritsche HA; Quesada JR
    Cancer Res; 1984 Sep; 44(9):4164-71. PubMed ID: 6430557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
    Marsman D
    Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients.
    Bain VG; Kaita KD; Yoshida EM; Swain MG; Heathcote EJ; Neumann AU; Fiscella M; Yu R; Osborn BL; Cronin PW; Freimuth WW; McHutchison JG; Subramanian GM
    J Hepatol; 2006 Apr; 44(4):671-8. PubMed ID: 16487617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Free interferon-alpha/beta receptors in the circulation of patients with adenocarcinoma.
    Ambrus JL; Dembinski W; Ambrus JL; Sykes DE; Akhter S; Kulaylat MN; Islam A; Chadha KC
    Cancer; 2003 Dec; 98(12):2730-3. PubMed ID: 14669296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.